Elderly Patients with Idiopathic Pulmonary Hypertension: Clinical Characteristics, Survival, and Risk Stratification in a Single-Center Prospective Registry.
Natalia GoncharovaKirill LapshinAelita BerezinaSimakova MariaAlexandr MarichevIrina ZlobinaNarek MarukyanKirill MalikovAlexandra AseevaVadim ZaitsevOlga MoiseevaPublished in: Life (Basel, Switzerland) (2024)
Risk stratification in the elderly IPAH patients requires a fundamentally different approach than that of younger patients, taking into account the initial limitations in physical performance and comorbidities that interfere with current assessment scores. The REVEAL score reliably stratifies patients at any age and LHD comorbidities. The initial monotherapy seems to be reasonable in patients over 60 years. Selection tools for initial combination PAH therapy in older IPAH patients with comorbidities need to be validated in prospective observational studies.
Keyphrases
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- pulmonary hypertension
- prognostic factors
- peritoneal dialysis
- stem cells
- gene expression
- clinical trial
- dna methylation
- mental health
- coronary artery
- middle aged
- pulmonary artery
- mesenchymal stem cells
- pulmonary arterial hypertension
- genome wide
- cell therapy
- combination therapy